Production (Stage)
Sharp Therapeutics Corp.
SHRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -164.60% | 88.01% | 88.01% | -- | -45.98% |
| Total Depreciation and Amortization | -36.26% | -4.96% | -4.96% | -- | 36.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 218.69% | -333.37% | -333.37% | -- | 122.71% |
| Change in Net Operating Assets | -323.89% | -412.18% | -412.18% | -- | -318.18% |
| Cash from Operations | -132.03% | -154.18% | -154.18% | -- | -16.48% |
| Capital Expenditure | -- | -- | -- | -- | -498.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -498.08% |
| Total Debt Issued | -- | 174.09% | 174.09% | -- | -- |
| Total Debt Repaid | 0.00% | -236.80% | -236.80% | -- | 0.00% |
| Issuance of Common Stock | -- | 108.35% | 108.35% | -- | 49,900.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -111.11% | 460.60% | 460.60% | -- | -24.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -710.71% | 4,611.30% | 4,611.30% | -- | -352.23% |